Hospital of the University of Pennsylvania

New Clinical Study Shows NeurOptics’ Neurological Pupil Index™, an Important Value for Assessing Brain Injury, is Unaffected by Clinical Intoxication

Retrieved on: 
Tuesday, January 10, 2023
Research, Medical Devices, Neurology, Hospitals, Clinical Trials, Biotechnology, Managed Care, Health, Science, ED, University, Emergency medicine, Neurological pupil index, Pupilometer, American College, Brain, Emergency, Trial of the century, Seizure, Attending physician, Ethanol, Hospital, Risk, Emergency department, Hospital of the University of Pennsylvania, AMS, Patient, Penn Presbyterian Medical Center, Journal, Stroke, NPI, Traumatic brain injury, Multimedia, Triage, Medical imaging

A newly published clinical study shows that NeurOptics’ Automated Pupillometry and the Neurological Pupil index™ (NPi®) remain unaffected by clinical intoxication, and therefore can be used for rapidly screening emergency room patients for brain injury or neurological injuries regardless of intoxicated state.

Key Points: 
  • A newly published clinical study shows that NeurOptics’ Automated Pupillometry and the Neurological Pupil index™ (NPi®) remain unaffected by clinical intoxication, and therefore can be used for rapidly screening emergency room patients for brain injury or neurological injuries regardless of intoxicated state.
  • View the full release here: https://www.businesswire.com/news/home/20230110005401/en/
    NeurOptics’ automated pupillometer has emerged as an important technology that provides a reliable measurement of pupil size and reactivity, expressed as the Neurological Pupil index (NPi).
  • The results showed that although clinical intoxication did affect pupil size and other individual metrics of the pupillary light reflex, no statistical differences in the NPi were noted between those with intoxication versus control patients.
  • NPi remained unaffected by clinical intoxication and therefore can potentially be used for ED patient evaluation without risk of confounding by key intoxicants of abuse.

ixlayer Announces Formation of Advisory Board

Retrieved on: 
Tuesday, November 1, 2022
Technology, Health Technology, Telemedicine, Virtual Medicine, Software, Practice Management, Other Health, General Health, Pharmaceutical, Health, Data Management, GSK, Retirement, Pharmacy, United States Coast Guard Auxiliary, COPE, Morristown Medical Center, COVID-19, Hospital, MHRI, Foundation, Kaiser Permanente, The Honourable, DTRA, Solution, GlaxoSmithKline, Clinton Foundation, Outreach, Operation Warp Speed, Board, Director, Head, Global Vaccines, Research, University, Veterans' affairs, Patient, Multimedia, University of Pennsylvania Health System, Senior, Movement, Drexel University School of Public Health, The Co Founder, Medical college, Editorial board, Time, Health, Decentralized Trials & Research Alliance, Therapeutic Innovation & Regulatory Science, Founder, Sarcoidosis, Pfizer, Salesforce, Health care, Hospital of the University of Pennsylvania, Innovation, Aetna, Government, Temple University Hospital, Pharmaceutical industry, Management, Medicine

ixlayer , the leading platform for health testing, announces today the formation of the ixlayer Health Testing Advisory Board .

Key Points: 
  • ixlayer , the leading platform for health testing, announces today the formation of the ixlayer Health Testing Advisory Board .
  • The ixlayer Health Testing Advisory Board will consist of industry leaders and experts who will serve as thought partners and strategists to further the movement of making health testing more accessible and affordable.
  • View the full release here: https://www.businesswire.com/news/home/20221101005418/en/
    ixlayer is appointing five members to its recently established ixlayer Heath Testing Advisory Board (iHTAB).
  • ixlayer is excited to take these next bold steps on our journey and welcomes these talented and respected professionals to our new advisory board, said Pouria Sanae , ixlayers Chief Executive Officer and co-founder.

Top Healthcare Executives Join Kaia Health’s Newly Created Advisory Board

Retrieved on: 
Thursday, October 13, 2022
Technology, Medical Devices, Fitness & Nutrition, Health Technology, Telemedicine, Virtual Medicine, Software, Biotechnology, Physical Therapy, Health, People, Health, Apple, Veteran, McKinsey & Company, Therapy, Medicine, COPD, Hospital, Growth, Partner, Smartphone, COO, General counsel, Patient, Kaia, MSK, Medical college, University of Pennsylvania Health System, Technology, Modern Healthcare, Forrester Research, University, Morristown Medical Center, Company, Blue Cross Blue Shield Association, The Honourable, AI, Board, CEO, Altran Praxis, DTA, Safety, Lists of diseases, Hospital of the University of Pennsylvania, Advisory board, The Advisory Board Company, ACA, Program, Temple University Hospital, Leadership, Pharmaceutical industry, Management, Healthcare

Kaia Health , the largest global digital therapeutics company on a mission to deliver the most effective digital therapies anytime, anywhere, today announced the appointment of four industry leaders to its newly created Advisory Board.

Key Points: 
  • Kaia Health , the largest global digital therapeutics company on a mission to deliver the most effective digital therapies anytime, anywhere, today announced the appointment of four industry leaders to its newly created Advisory Board.
  • is an accomplished executive who has devoted his career to making a positive impact across the healthcare value chain.
  • Steve serves on a number of boards and as a senior advisor to many of the leading players in healthcare.
  • I am honored to join the Advisory Board and support Kaias mission to advance the availability, quality and affordability of healthcare."

Proscia Releases New Version Of Concentriq Dx Enabling Laboratories To Achieve 100% Digital Diagnosis

Retrieved on: 
Wednesday, October 12, 2022
Dark, Adoption, Laboratory, Digital Pathology Association, Occupational burnout, Hospital, Pathology, Diagnosis, List of pathologists, Patient, IVDR, Research, Medical laboratory, Cancer, University, MD, Department, S, Health, Hospital of the University of Pennsylvania, Marie Cassidy, COVID-19, Solution, Public health, Medical device, Pharmaceutical industry, Medical imaging

PHILADELPHIA, Oct. 12, 2022 /PRNewswire-PRWeb/ -- Proscia®, a leading provider of digital and computational pathology solutions, has introduced the next version of its Concentriq® Dx platform for primary diagnostic workflows, which is CE-marked under IVDR*. The release brings together new features and a compelling user experience to help even the largest laboratory networks transition to 100% digital diagnosis. In doing so, they can realize the full promise of the shift away from microscope-based pathology.

Key Points: 
  • The release brings together new features and a compelling user experience to help even the largest laboratory networks transition to 100% digital diagnosis.
  • Trusted by top laboratories and health systems, Concentriq Dx is a secure, AI-ready digital pathology platform that powers primary diagnostic workflows.
  • To learn more about Concentriq Dx and see a demo, visit Proscia at booth 315 during Pathology Visions, the Digital Pathology Association's annual meeting.
  • *Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.

IconOVir Bio Appoints Julia Maltzman, M.D., as Chief Medical Officer

Retrieved on: 
Monday, October 10, 2022
Health, General Health, LinkedIn, Nektar Therapeutics, Therapy, Hospital, GlaxoSmithKline, Growth, Acceleration, Drug, Patient, Drug development, Cancer immunotherapy, Internal medicine, Gilead Sciences, Cancer, Technology, University, Pharmacovigilance, Faculty, Hospital of the University of Pennsylvania, University of Colorado School of Medicine, Salk Institute for Biological Studies, Â, OV, Leadership, Pharmaceutical industry, Genentech

IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of Julia (Julie) Maltzman, M.D., as its Chief Medical Officer.

Key Points: 
  • IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced the appointment of Julia (Julie) Maltzman, M.D., as its Chief Medical Officer.
  • At IconOVir, Dr. Maltzman will lead all activities associated with the clinical development of the IconOVirs emerging OV-based therapeutic pipeline, including clinical development, clinical operations, medical affairs and pharmacovigilance activities.
  • We are thrilled to welcome Julie to our team as we prepare to advance ICVB-1042, our lead product candidate, into first-in-human Phase 1 studies next year, said Mark McCamish, M.D., Ph.D., President and Chief Executive Officer of IconOVir.
  • Dr. Maltzman joins IconOVir from Genentech, where she most recently served as Franchise Head, Vice President and Global Head of Gastrointestinal (GI) and Cancer Immunotherapy.

Median Technologies Announces Formation of Clinical Advisory Board for iBiopsy® Lung Cancer Screening

Retrieved on: 
Monday, October 3, 2022
Biotechnology, Medical Devices, Other Health, Health, Oncology, LCS, Liver cancer, University of Pennsylvania Health System, Hospital, Journal of Thoracic Oncology, Precision medicine, Knowledge, Data science, HCC, Icahn School of Medicine at Mount Sinai, Radiology, Technology, SME, Division, Intervention, Mount Auburn Hospital, Associate professor, Cave rescue, NASH, View, Lung cancer, Software, University of Insubria, Hospital of the University of Pennsylvania, CCO, Cancer, Patient, Lung cancer screening, Diagnosis, University, Faculty, Clinical research, CAB, Prognosis, Physician, Critical care, Lists of diseases, BPI, Cirrhosis, Associate, Department, COO, Section, DS, Solution, Oncology, Medical device, Harvard Medical School, Artificial intelligence, Medical imaging, Medicine, Mount Sinai Morningside

Median Technologies (Paris:ALMDT) announced today the formation of their Clinical Advisory Board (CAB) for iBiopsy Lung Cancer Screening.

Key Points: 
  • Median Technologies (Paris:ALMDT) announced today the formation of their Clinical Advisory Board (CAB) for iBiopsy Lung Cancer Screening.
  • I am pleased and honored to be working with this team of distinguished and highly accomplished clinicians, whos wealth of knowledge and experience will help Median deliver on optimizing the Lung Cancer Screening routine and saving patient lives.
  • iBiopsy currently focuses on lung cancer, liver cancer (HCC) and liver fibrosis (NASH).
  • About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone.

Verismo Therapeutics Receives U.S. FDA Orphan Drug Designation for SynKIR-110™, a First-in-Class KIR-CAR T Cell Immunotherapy Candidate, for the Treatment of Mesothelioma

Retrieved on: 
Wednesday, September 28, 2022
Biomedical Advanced Research and Development Authority, Gene editing, ODD, FDA, Food, Cholangiocarcinoma, Hospital, Hospital of the University of Pennsylvania, Mesothelioma, PDUFA, Therapy, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cancer, CEO, Life expectancy, Diagnosis, Overalls, Marketing, University, Penn, Disease, CAR, Orphan, Pharmaceutical industry, Medical imaging, Verismo

PHILADELPHIA, Sept. 28, 2022 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR-T company and Penn spinout, and pioneer of the novel KIR-CAR platform technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to SynKIR-110™ for the treatment of patients with mesothelin-expressing mesotheliomas.

Key Points: 
  • "Orphan Drug Designation is another major milestone for Verismo following the acceptance of our SynKIR-110IND," said Dr. Bryan Kim, CEO of Verismo.
  • "Mesotheliomais a rare and deadly disease for which few other treatment options currently exist.
  • Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, on track to bring its first asset into first-in-human clinical trials in 2023.
  • Verismo is the only company developing the KIR-CAR platform, amodified NK-like receptor designed to improve persistence and efficacy against aggressive solid tumors.

Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate

Retrieved on: 
Tuesday, September 20, 2022
Biomedical Advanced Research and Development Authority, Safety, Gene editing, FDA, Food, Cholangiocarcinoma, Hospital, Ovarian cancer, Hospital of the University of Pennsylvania, IND, Therapy, Neoplasm, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CEO, Technology, Cell, CSO, University, Mesothelioma, Penn, CAR, Pharmaceutical industry, Vaccine, Verismo

PHILADELPHIA, Sept. 20, 2022 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage biotechnology company and a Penn-spinout behind the novel KIR-CAR platform technology, today announced that is has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110.

Key Points: 
  • For each indication, the five-year survival rates are 49.7% for ovarian cancer, 30% for cholangiocarcinoma and 10% for mesothelioma.
  • STAR-101 will mark the first-in-human study for SynKIR T cells, a next generation approach to cell therapy targeting solid tumors powered by the KIR-CAR platform.
  • The FDA's clearance of our SynKIR-110 IND represents a new chapter for Verismo as we initiate the first-ever clinical trial for KIR-CAR T cells.
  • Verismo Therapeutics is a pioneer in dual-chain KIR-CAR T cell technology, on track to bring its first asset into first-in-human clinical trials in 2023.

FDA Grants IDE Approval to Evaluate Attune Medical’s ensoETM in Radiofrequency Ablation Procedures

Retrieved on: 
Thursday, September 8, 2022
Research, Medical Devices, Surgery, FDA, Clinical Trials, Cardiology, Radiology, General Health, Health, Science, Lung, Santang, National, University, Catheter ablation, DRS, Hospital of the University of Pennsylvania, Doctor of Philosophy, Associate, US Foods, National Heart, Lung, and Blood Institute, Heart, Temperature, Esophagus, IDE, Electrophysiology, Food, Small Business Innovation Research, Research assistant, Paola Lattus, Hospital, SBIR, FDA, Mercer (consulting firm), Atrial fibrillation, IMPACT, NOT, Patient, Medical device, Pharmaceutical industry, Medicine, EP Europace

The US Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to Attune Medical to evaluate the companys ensoETM in the reduction of esophageal thermal injury during cardiac radiofrequency ablation procedures.

Key Points: 
  • The US Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to Attune Medical to evaluate the companys ensoETM in the reduction of esophageal thermal injury during cardiac radiofrequency ablation procedures.
  • Thermal injury during RF ablation procedures is a major concern in electrophysiology, commented Dr. Santangeli.
  • The data from this study will be used to expand the ensoETMs intended use in the US to include reduction of esophageal thermal injury during cardiac radiofrequency ablation procedures.
  • The ensoETM has NOT been approved or cleared by the FDA to reduce thermal injury to the esophagus during radiofrequency cardiac ablation procedures.

Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board

Retrieved on: 
Wednesday, September 7, 2022
Harvard Medical School, Massachusetts General Hospital, University, Icahn School of Medicine at Mount Sinai, COVID-19, Inflammatory bowel disease, UC, Research, DDS, Hospital of the University of Pennsylvania, Fasting, Therapy, SAN, MGH, VARSITY, Disease, Colon, Precision medicine, Tissue, Result, Blood, Internal medicine, Boston University, GI, IBD, SEC, Quality of life, Goal, Faculty, BA, MD, GLOBE, Hospital, UNIFI, Nasdaq, The New England Journal of Medicine, Financial condition report, Inflammatory Bowel Diseases, Annual report, Private Securities Litigation Reform Act, Analysis, Ulcerative colitis, Trial of the century, Patient, Medical device, Pharmaceutical industry, Medicine, Gastroenterology

(Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also includes leading IBD researchers Dr. Geert DHaens, Dr. Brian Feagan, and Dr. Sverine Vermeire.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also includes leading IBD researchers Dr. Geert DHaens, Dr. Brian Feagan, and Dr. Sverine Vermeire.
  • The clinical advisory board provides strategic guidance on clinical development of Bioras Targeted Therapeutics pipeline .
  • Im pleased to accept this role as chair of the IBD clinical advisory board and help progress these urgently needed therapies into the clinic.
  • We thank Dr. Bruce Sands, who is one of the leading minds in IBD clinical research, for his commitment to serve as chair of our advisory board, said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.